{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,16]],"date-time":"2026-06-16T09:58:59Z","timestamp":1781603939357,"version":"3.54.5"},"reference-count":35,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"7","license":[{"start":{"date-parts":[[2025,2,14]],"date-time":"2025-02-14T00:00:00Z","timestamp":1739491200000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2025,2,14]]},"abstract":"<jats:sec>\n            <jats:title>Background:<\/jats:title>\n            <jats:p>Sodium\u2013glucose cotransporter 2 (SGLT2) inhibitors (such as dapagliflozin, empagliflozin, and canagliflozin) are essential for the treatment of type 2 diabetes because they improve the urine excretion of glucose. Although there are advantages, including weight loss and enhanced heart health, caution is necessary because of possible negative effects, such as higher urine output and euglycemic diabetic ketoacidosis. They may slow chronic kidney disease progression, therefore, renal function must be monitored. This study aims to determine the efficacy of SGLT2 inhibitors in the prevention of renal deterioration in terms of reduction of estimated glomerular filtration rate (eGFR) in patients with compromised renal functions.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Methods:<\/jats:title>\n            <jats:p>This study aimed to document the long-term effects of SGLT2 inhibitors on kidney function. PubMed and Google Scholar were the key sources of scholarly publications, and Boolean operators were used to perform exact searches. Nine articles were considered relevant out of a total of 244, following extensive screening of titles, abstracts, and full texts according to PRISMA recommendations.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Results:<\/jats:title>\n            <jats:p>This study included randomized, double-blind, placebo-controlled trials evaluating the long-term effects of SGLT2 inhibitors on renal function across patient demographics and locations. Clinical investigations showed different effects on eGFR across control and study groups, suggesting renal protection. A meta-analysis showed that SGLT2 inhibitors enhanced kidney function more than the controls.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Conclusion:<\/jats:title>\n            <jats:p>This meta-analysis concluded that SGLT2 inhibitors have the potential to prevent eGFR reduction and improve renal function in patients with compromised renal function and underlying conditions such as chronic kidney disease or type 1 and 2 diabetes. However, this meta-analysis showed beneficial results in the prevention of renal deterioration within several follow-up periods, with an average of 11 to 12 months.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1097\/md.0000000000041422","type":"journal-article","created":{"date-parts":[[2025,2,17]],"date-time":"2025-02-17T19:00:46Z","timestamp":1739818846000},"page":"e41422","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":4,"title":["Long-term effect of sodium\u2013glucose cotransporter 2 inhibitors in kidney functions: A systematic review and meta-analysis"],"prefix":"10.1097","volume":"104","author":[{"given":"Yanqun","family":"Zheng","sequence":"first","affiliation":[{"name":"Department of Nephrology, The First People\u2019s Hospital of Linping District, Hangzhou, China."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jia","family":"Sun","sequence":"additional","affiliation":[{"name":"Department of Nephrology, The First People\u2019s Hospital of Linping District, Hangzhou, China."}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"R1-20250217","doi-asserted-by":"crossref","first-page":"2118","DOI":"10.1007\/s00125-018-4663-6","article-title":"Use of SGLT2 inhibitors in type 2 diabetes: weighing the risks and benefits.","volume":"61","author":"Lupsa","year":"2018","journal-title":"Diabetologia"},{"key":"R2-20250217","doi-asserted-by":"crossref","first-page":"463","DOI":"10.1517\/13543784.2013.774372","article-title":"Differentiating sodium\u2013glucose co-transporter-2 inhibitors in development for the treatment of type 2 diabetes mellitus.","volume":"22","author":"Washburn","year":"2013","journal-title":"Expert Opin Investig Drugs"},{"key":"R3-20250217","doi-asserted-by":"crossref","first-page":"110192","DOI":"10.1016\/j.biopha.2020.110192","article-title":"Combination therapy with SGLT2 inhibitors for diabetic kidney disease.","volume":"127","author":"Cai","year":"2020","journal-title":"Biomed Pharmacother"},{"key":"R4-20250217","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1111\/1753-0407.13007","article-title":"Cardiorenal protection with SGLT2: lessons from the cardiovascular outcome trials.","volume":"12","author":"Silva-Cardoso","year":"2020","journal-title":"J Diabetes"},{"key":"R5-20250217","doi-asserted-by":"crossref","first-page":"86","DOI":"10.2174\/1871529X18666180206130218","article-title":"Sodium\u2013glucose cotransporter 2 inhibitors: the pleiotropic mechanisms of actions.","volume":"18","author":"Pantelidis","year":"2018","journal-title":"Cardiovasc Hematol Disord Drug Targets"},{"key":"R6-20250217","doi-asserted-by":"crossref","first-page":"161","DOI":"10.4103\/2229-516X.165363","article-title":"Sodium glucose co-transporter inhibitors \u2013 a new class of old drugs.","volume":"5","author":"Malhotra","year":"2015","journal-title":"Int J Appl Basic Med Res"},{"key":"R7-20250217","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1007\/s11892-016-0789-4","article-title":"SGLT2 inhibitors: benefit\/risk balance.","volume":"16","author":"Scheen","year":"2016","journal-title":"Curr Diab Rep"},{"key":"R9-20250217","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1016\/S0025-7753(13)70060-5","article-title":"Contribuci\u00f3n del ri\u00f1\u00f3n en la homeostasis de la glucosa.","volume":"141","author":"Segura","year":"2013","journal-title":"Med Clin"},{"key":"R10-20250217","doi-asserted-by":"crossref","first-page":"110489","DOI":"10.1016\/j.jtbi.2020.110489","article-title":"A phenomenological-based semi-physical model of the kidneys and its role in glucose metabolism.","volume":"508","author":"Lema-Perez","year":"2021","journal-title":"J Theor Biol"},{"key":"R11-20250217","doi-asserted-by":"crossref","first-page":"e018889","DOI":"10.1161\/JAHA.120.018889","article-title":"Glucose metabolism in the kidney: neurohormonal activation and heart failure development.","volume":"9","author":"Gronda","year":"2020","journal-title":"J Am Heart Assoc"},{"key":"R12-20250217","first-page":"A8106","article-title":"The relevance of a decline in renal function for risk of renal failure, cardiovascular events and all-cause mortality.","volume":"1591","author":"Bots","year":"2015","journal-title":"Ned Tijdschr Geneeskd"},{"key":"R13-20250217","doi-asserted-by":"crossref","first-page":"S7","DOI":"10.1111\/j.1523-1755.2005.09902.x","article-title":"The need for optimal and coordinated management of CKD.","volume":"68","author":"Levin","year":"2005","journal-title":"Kidney Int"},{"key":"R14-20250217","doi-asserted-by":"crossref","first-page":"15266","DOI":"10.3390\/ijerph192215266","article-title":"Assessment of health-related quality of life, medication adherence, and prevalence of depression in kidney failure patients.","volume":"19","author":"Butt","year":"2022","journal-title":"Int J Environ Res Public Health"},{"key":"R15-20250217","doi-asserted-by":"crossref","first-page":"267","DOI":"10.14740\/jocmr3761","article-title":"Renoprotective effects of additional SGLT2 inhibitor therapy in patients with type 2 diabetes mellitus and chronic kidney disease stages 3b\u20134: a real world report from a Japanese specialized diabetes care center.","volume":"11","author":"Sugiyama","year":"2019","journal-title":"J Clin Med Res"},{"key":"R16-20250217","doi-asserted-by":"crossref","first-page":"317507","DOI":"10.1155\/2015\/317507","article-title":"Sodium\u2013glucose linked transporter-2 inhibitors in chronic kidney disease.","volume":"2015","author":"Zanoli","year":"2015","journal-title":"Sci World J"},{"key":"R17-20250217","doi-asserted-by":"crossref","first-page":"e3303","DOI":"10.1002\/dmrr.3303","article-title":"Long-term renal outcomes associated with sodium glucose cotransporter 2 inhibitors in patients with type 2 diabetes mellitus: a systematic review and meta-analysis.","volume":"36","author":"Zhang","year":"2020","journal-title":"Diabetes Metab Res Rev"},{"key":"R18-20250217","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1080\/00325481.2019.1601404","article-title":"SGLT2 inhibitors in patients with type 2 diabetes and renal disease: overview of current evidence.","volume":"131","author":"Davidson","year":"2019","journal-title":"Postgrad Med"},{"key":"R19-20250217","doi-asserted-by":"crossref","first-page":"n71","DOI":"10.1136\/bmj.n71","article-title":"The PRISMA 2020 statement: an updated guideline for reporting systematic reviews.","volume":"372","author":"Page","year":"2021","journal-title":"BMJ"},{"key":"R20-20250217","doi-asserted-by":"crossref","first-page":"328","DOI":"10.1053\/j.ajkd.2019.03.417","article-title":"Safety and effectiveness of bexagliflozin in patients with type 2 diabetes mellitus and stage 3a\/3b CKD.","volume":"74","author":"Allegretti","year":"2019","journal-title":"Am J Kidney Dis"},{"key":"R21-20250217","doi-asserted-by":"crossref","first-page":"2352","DOI":"10.1681\/ASN.2021020167","article-title":"Effects of dapagliflozin in stage 4 chronic kidney disease.","volume":"32","author":"Chertow","year":"2021","journal-title":"J Am Soc Nephrol"},{"key":"R22-20250217","doi-asserted-by":"crossref","first-page":"2532","DOI":"10.1111\/dom.13413","article-title":"Efficacy and safety of dapagliflozin in patients with type 2 diabetes and moderate renal impairment (chronic kidney disease stage 3A): the DERIVE study [published correction appears in Diabetes Obes Metab. 2019;21(1):203].","volume":"20","author":"Fioretto","year":"2018","journal-title":"Diabetes Obes Metab"},{"key":"R23-20250217","doi-asserted-by":"crossref","first-page":"845","DOI":"10.1016\/S2213-8587(20)30280-1","article-title":"Effect of dapagliflozin as an adjunct to insulin over 52 weeks in individuals with type 1 diabetes: post-hoc renal analysis of the DEPICT randomised controlled trials.","volume":"8","author":"Groop","year":"2020","journal-title":"Lancet Diabetes Endocrinol"},{"key":"R24-20250217","doi-asserted-by":"crossref","first-page":"298","DOI":"10.1161\/CIRCULATIONAHA.120.050391","article-title":"Efficacy of dapagliflozin on renal function and outcomes in patients with heart failure with reduced ejection fraction: results of DAPA-HF.","volume":"143","author":"Jhund","year":"2021","journal-title":"Circulation"},{"key":"R25-20250217","doi-asserted-by":"crossref","first-page":"606","DOI":"10.1016\/S2213-8587(19)30180-9","article-title":"Effects of dapagliflozin on development and progression of kidney disease in patients with type 2 diabetes: an analysis from the DECLARE-TIMI 58 randomised trial.","volume":"7","author":"Mosenzon","year":"2019","journal-title":"Lancet Diabetes Endocrinol"},{"key":"R26-20250217","doi-asserted-by":"crossref","first-page":"1413","DOI":"10.1056\/NEJMoa2022190","article-title":"Cardiovascular and renal outcomes with empagliflozin in heart failure.","volume":"383","author":"Packer","year":"2020","journal-title":"N Engl J Med"},{"key":"R27-20250217","doi-asserted-by":"crossref","first-page":"2295","DOI":"10.1056\/NEJMoa1811744","article-title":"Canagliflozin and renal outcomes in type 2 diabetes and nephropathy.","volume":"380","author":"Perkovic","year":"2019","journal-title":"N Engl J Med"},{"key":"R28-20250217","doi-asserted-by":"crossref","first-page":"1921","DOI":"10.2337\/dc19-0937","article-title":"The impact of Sotagliflozin on renal function, albuminuria, blood pressure, and hematocrit in adults with type 1 diabetes.","volume":"42","author":"van Raalte","year":"2019","journal-title":"Diabetes Care"},{"key":"R29-20250217","doi-asserted-by":"crossref","first-page":"1117","DOI":"10.1016\/j.dsx.2018.06.003","article-title":"SGLT2 inhibitors and the kidney: effects and mechanisms.","volume":"12","author":"Tsimihodimos","year":"2018","journal-title":"Diabetes Metab Syndr"},{"key":"R30-20250217","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1155\/2019\/3971060","article-title":"Long-term effectiveness and safety of SGLT-2 inhibitors in an Italian cohort of patients with type 2 diabetes mellitus.","volume":"2019","author":"Mirabelli","year":"2019","journal-title":"J Diabetes Res"},{"key":"R31-20250217","doi-asserted-by":"crossref","first-page":"1147","DOI":"10.1016\/j.kint.2022.05.031","article-title":"Kidney outcomes in patients with diabetes mellitus did not differ between individual sodium\u2013glucose cotransporter-2 inhibitors.","volume":"102","author":"Suzuki","year":"2022","journal-title":"Kidney Int"},{"key":"R32-20250217","doi-asserted-by":"crossref","first-page":"732","DOI":"10.1016\/j.xkme.2021.04.009","article-title":"SGLT2 inhibitors and kidney and cardiac outcomes according to estimated GFR and albuminuria levels: a meta-analysis of randomized controlled trials.","volume":"3","author":"Chun","year":"2021","journal-title":"Kidney Med"},{"key":"R33-20250217","doi-asserted-by":"crossref","first-page":"1860","DOI":"10.1007\/s00125-016-4008-2","article-title":"The effect of sodium glucose cotransporter 2 inhibition with empagliflozin on microalbuminuria and macroalbuminuria in patients with type 2 diabetes.","volume":"59","author":"Cherney","year":"2016","journal-title":"Diabetologia"},{"key":"R34-20250217","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1007\/s11892-018-0992-6","article-title":"New diabetes therapies and diabetic kidney disease progression: the role of SGLT-2 inhibitors.","volume":"18","author":"Dekkers","year":"2018","journal-title":"Curr Diab Rep"},{"key":"R35-20250217","doi-asserted-by":"crossref","first-page":"190","DOI":"10.1097\/MNH.0000000000000584","article-title":"Renal effects of SGLT2 inhibitors: an update.","volume":"29","author":"Nespoux","year":"2020","journal-title":"Curr Opin Nephrol Hypertens"},{"key":"R36-20250217","doi-asserted-by":"crossref","first-page":"1463","DOI":"10.1016\/j.ekir.2022.04.094","article-title":"Prescribing SGLT2 inhibitors in patients with CKD: expanding indications and practical considerations.","volume":"7","author":"Yau","year":"2022","journal-title":"Kidney Int Rep"}],"container-title":["Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/MD.0000000000041422","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,2,17]],"date-time":"2025-02-17T19:00:55Z","timestamp":1739818855000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/MD.0000000000041422"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,2,14]]},"references-count":35,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2025]]}},"URL":"https:\/\/doi.org\/10.1097\/md.0000000000041422","relation":{},"ISSN":["1536-5964"],"issn-type":[{"value":"1536-5964","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,2,14]]}}}